510 related articles for article (PubMed ID: 15302800)
1. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
2. Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Lekakis JP; Vamvakou G; Andreadou I; Ganiatsos G; Karatzis E; Protogerou A; Papaioannou T; Ikonomidis I; Papamichael C; Mavrikakis ME
Int J Cardiol; 2006 Oct; 112(3):359-66. PubMed ID: 16330117
[TBL] [Abstract][Full Text] [Related]
3. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
Brown DL; Desai KK; Vakili BA; Nouneh C; Lee HM; Golub LM
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):733-8. PubMed ID: 14962945
[TBL] [Abstract][Full Text] [Related]
6. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
7. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
Chyrchel M; Dudek D; Bartuś S; Legutko J; Heba G; Dubiel JS
Kardiol Pol; 2004 Sep; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
9. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
[TBL] [Abstract][Full Text] [Related]
10. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis.
Wong M; Jiang BY; McNeill K; Farish S; Kirkham B; Chowienczyk P
Scand J Rheumatol; 2007; 36(4):265-9. PubMed ID: 17763203
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
12. Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease.
Tikiz C; Utük O; Bayturan O; Bayindir P; Ekmekçi C; Tikiz H
Acta Med Okayama; 2005 Feb; 59(1):11-7. PubMed ID: 15902994
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors.
Wang XM; Wu TX; Lee YS; Dionne RA
Clin Pharmacol Ther; 2006 Apr; 79(4):303-15. PubMed ID: 16580899
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
Schwartz JI; Chan CC; Mukhopadhyay S; McBride KJ; Jones TM; Adcock S; Moritz C; Hedges J; Grasing K; Dobratz D; Cohen RA; Davidson MH; Bachmann KA; Gertz BJ
Clin Pharmacol Ther; 1999 Jun; 65(6):653-60. PubMed ID: 10391671
[TBL] [Abstract][Full Text] [Related]
15. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
Kuklińska AM; Musiał WJ; Kamiński KA; Kralisz P; Modrzejewski W; Sobkowicz B; Dobrzycki S; Stec S; Wojtkowska I
Rocz Akad Med Bialymst; 2005; 50():339-42. PubMed ID: 16358997
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
[TBL] [Abstract][Full Text] [Related]
17. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
18. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.
Zhao SP; Liu L; Cheng YC; Shishehbor MH; Liu MH; Peng DQ; Li YL
Circulation; 2004 Aug; 110(8):915-20. PubMed ID: 15313947
[TBL] [Abstract][Full Text] [Related]
19. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
[TBL] [Abstract][Full Text] [Related]
20. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
